Guardant Health, Inc. (GH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Core Viewpoint - The discussion centers around the clinical utility of the ESR1 mutation discovery and its implications for liquid biopsy, particularly in the context of the SERENA-6 protocol design [1] Group 1 - There are ongoing conversations regarding the SERENA-6 study and its protocol design, which have sparked interest and debate within the biotech community [1] - The clinical utility of identifying the ESR1 mutation is highlighted, emphasizing its broader implications for patient care and treatment decisions [1] - The focus is on the benefits of testing and the potential for patient outcomes without delving into specific drug discussions [1]